We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-10.83%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.11B
AUM Growth
-$229M
(-9.8%)
Cap. Flow
+$212M
Cap. Flow
% of AUM
10.07%
Top 10 Holdings %
Top 10 Hldgs %
55.22%
Holding
39
New
13
Increased
14
Reduced
3
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$111M |
| 2 |
GSK
GSK
|
+$78.8M |
| 3 |
Perrigo
PRGO
|
+$76.2M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$70.9M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$46.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HCA Healthcare
HCA
|
+$101M |
| 2 |
EVHC
Envision Healthcare Holdings Inc
EVHC
|
+$62M |
| 3 |
TSRO
TESARO, Inc.
TSRO
|
+$33.6M |
| 4 |
KTWO
K2M Group Holdings, Inc
KTWO
|
+$27.4M |
| 5 |
Biogen
BIIB
|
+$16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Zymeworks
ZYME
$1.61B
| $31.8M | 1.51% |
2,166,000
+793,000
| +58% | +$10.4M |
|
|
27
HCA Healthcare
HCA
$87.2B
| $31.1M | 1.48% |
250,000
-750,000
| -75% | -$101M |
|
28
CALL
Viatris
VTRS
$20.4B
| $27.4M | 1.3% |
+1,000,000
| New | +$32.4M |
|
29
Puma Biotechnology
PBYI
$404M
| $26.5M | 1.26% |
1,300,000
+550,000
| +73% | +$16.5M |
|
|
ARNA
30
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $19.5M | 0.92% |
+500,000
| New | +$19.6M |
|
31
Bausch Health
BHC
$2.58B
| $18.5M | 0.88% |
+1,000,000
| New | +$23.8M |
|
|
EGRX
32
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $11.7M | 0.56% |
291,600
| – | – |
|
33
DaVita
DVA
$15.4B
| $8.62M | 0.41% |
+167,528
| New | +$10.7M |
|
|
ELGX
34
DELISTED
Endologix Inc
ELGX
| $6.66M | 0.32% |
930,000
| – | – |
|
35
Sutro Biopharma
STRO
$401M
| $5.41M | 0.26% |
60,000
| – | – |
|
36
Surgery Partners
SGRY
$2.01B
| $1.57M | 0.07% |
160,084
+25,000
| +19% | +$336K |
|
37
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
| – | – |
-2,000,000
| Closed | -$581M |
|
|
KTWO
38
DELISTED
K2M Group Holdings, Inc
KTWO
| – | – |
-1,000,000
| Closed | -$27.4M |
|
|
EVHC
39
DELISTED
Envision Healthcare Holdings Inc
EVHC
| – | – |
-1,355,000
| Closed | -$62M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q4 2018 Portfolio in Review
As of Q4 2018, Camber Capital Management held 39 positions worth $2.11B, down 9.8% from $2.34B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Camber Capital Management deployed $212M of net new capital in Q4 2018, opening 13 new positions and adding to 14 existing holdings. Its largest new stake was Celgene Corp: 1,500,000 shares worth $96.1M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 70% a quarter earlier.
On the sell side, the largest reduction was HCA Healthcare, an estimated $101M trimmed.
- Camber Capital Management's largest Q4 2018 buy was Celgene Corp: 1,500,000 shares worth $96.1M.
- Camber Capital Management added most to Perrigo in Q4 2018, an estimated $76.2M increase.
- Camber Capital Management's biggest Q4 2018 reduction was HCA Healthcare, cutting an estimated $101M.
- Camber Capital Management fully exited Envision Healthcare Holdings Inc in Q4 2018, selling an estimated $62M.
- Camber Capital Management's ten largest holdings make up 55% of its $2.11B portfolio in Q4 2018.
- Camber Capital Management opened 13 new positions and closed 3 in Q4 2018.
- Camber Capital Management's portfolio value fell 9.8% quarter-over-quarter to $2.11B.
Based on Camber Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.